What We Offer
Discover our comprehensive range of health & medical services
Health Resources
Januskinases.com provides comprehensive educational resources on Janus kinase biology, JAK inhibitor medications, and the diseases they treat, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and myeloproliferative neoplasms. The JAK-STAT signaling pathway is one of the most studied intracellular signal transduction systems in modern immunology and hematology. Resources include explanations of how JAK1, JAK2, JAK3, and TYK2 differ in their receptor associations and downstream effects. All health information is reviewed against current clinical guidelines from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).
Research Database
The JAK kinase research database compiles peer-reviewed literature on JAK-STAT pathway biology, clinical trial data for FDA-approved JAK inhibitors, and emerging research on next-generation selective inhibitors. Currently approved JAK inhibitors include tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), abrocitinib (Cibinqo), ruxolitinib (Jakafi/Opzelura), fedratinib (Inrebic), pacritinib (Vonjo), and filgotinib (Jyseleca, approved outside the US). Clinical trial databases including ClinicalTrials.gov are regularly searched to maintain current information on investigational JAK inhibitors in development. The database is organized by drug, target kinase, disease indication, and mechanism of action.
Patient Community
The JAK inhibitor patient community connects individuals living with autoimmune conditions — including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and atopic dermatitis — who are taking or considering JAK inhibitor therapies. Patient forums provide a space to share treatment experiences, discuss side effect management, and ask questions that can be reviewed with healthcare providers. The 2021 FDA black box warning updates for JAK inhibitors, which highlighted elevated risks of cardiovascular events, malignancy, and thrombosis, generated significant questions among the patient community. All medical discussions are accompanied by guidance to consult licensed healthcare professionals before making treatment decisions.
Health Assessments
JAK inhibitor therapy suitability involves consideration of multiple patient-specific factors including cardiovascular risk, age, prior treatment history with biologic DMARDs, infection risk, and smoking status. FDA prescribing guidelines for JAK inhibitors specify that they should generally be used after an inadequate response or intolerance to methotrexate or other DMARDs, and after a TNF inhibitor in certain patient populations. Monitoring recommendations during JAK inhibitor therapy include periodic complete blood counts, liver function tests, lipid panels, and assessment for signs of infection and malignancy. Educational assessments help patients understand the risk-benefit framework physicians use when selecting between biologic and JAK inhibitor therapies.
Educational Content
Educational content on JAK kinase biology covers the discovery of Janus kinases in the early 1990s by researchers including James Darnell, George Stark, and Ian Kerr, who identified the JAK-STAT pathway as the signal transduction mechanism for interferons. Tofacitinib's approval by the FDA in 2012 as the first JAK inhibitor for rheumatoid arthritis marked a major milestone in the development of targeted small-molecule therapies for autoimmune disease. Detailed explanations of STAT protein structure, the pseudo-kinase (JH2) domain of JAK proteins that regulates kinase activity, and the molecular basis of selectivity differences between JAK inhibitors are provided for researchers and clinicians. The content is suitable for medical students, advanced undergraduate biology students, and non-specialist clinicians seeking to understand the pharmacology of this drug class.
Expert Consultations
Expert consultations on JAK inhibitor therapy are available through connections to board-certified rheumatologists, dermatologists, hematologist-oncologists, and gastroenterologists who specialize in managing conditions treated with JAK inhibitors. Consultation services include disease activity assessment, treatment history review, and guidance on transitioning between biologic and JAK inhibitor therapies. Second-opinion consultations are particularly valuable for patients with complex comorbidities such as prior malignancy, active infection history, or significant cardiovascular risk factors, where the benefit-risk calculation for JAK inhibitor therapy requires careful individualization. All consultation services emphasize shared decision-making between the patient and their primary treating physician.